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198Objective: Transcatheter pulmonary valve insertion has recently emerged as an alternative to surgery. To extend its
indications to patients with a large right ventricular outflow tract, we previously developed an intravascular device that
reduces the diameter of the main pulmonary artery, allowing the insertion of available valved stents. Here we report its
use in a model of animals with an enlarged right ventricular outflow tract and pulmonary valve incompetence.
Methods and Results: The study comprised 33 sheep that first underwent surgical enlargement of the main pul-
monary artery. We then intended to implant a filler percutaneously, followed later by the insertion of a valve.
Three animals died during the intermediate stage. The remainder were humanely killed either immediately (group
1, n¼ 6) or after a mean follow-up of 1 (group 2, n¼ 12) or 2 months (group 3, n¼ 12). Animals from groups 2
and 3 were equally divided into 2 subgroups according to the difference between diameters of the device inserted
and the main pulmonary artery (A<5 mm, B  5 mm). Fillers were all inserted successfully (n ¼ 30), although
one embolized after its insertion (group 3A). A valved stent was implanted in all animals, but in 1 case a balloon
ruptured during inflation of the stent leading to incomplete expansion and the death of the animal. Six animals, 5
of which were from group A, had pulmonary regurgitation after valve insertion.
Conclusion: Pulmonary valve insertion is possible through a transcatheter technique using a pulmonary artery
filler. Oversizing the device reduces the risk of embolization and paraprosthetic leak. (J Thorac Cardiovasc
Surg 2010;139:198-208)Pulmonary valve incompetence (PVI), although generally
well tolerated at short-term ormidterm follow-up, has clearly
been identified as a risk factor leading to significant long-
termmorbidity andmortality.1-3 In fact, it results in right ven-
tricular (RV) dilatation, chronic heart failure, and ventricular
arrhythmias.4-12 The only way to correct this insufficiency is
to surgically replace the pulmonary valve (PV).9,12 A trans-
catheter technique to insert a PV has been developed.13-15
The only valve widely used and authorized for this indication
in Europe is the Melody valve (Medtronic Inc, Minneapolis,
Minn). Its use is presently limited to the small number of pa-
tients having a nonnative RV–pulmonary artery (PA) con-
nection smaller than 22 mm in diameter. Patients operated
on for tetralogy of Fallot represent most of the patients in
need of a PV. They are often excluded from this technique
because of the diameter of their right ventricular outflow tract
(RVOT). As a result, these patients are only treatable by
surgery. In parallel, off-pump PV insertion has been
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The Journal of Thoracic and Cardiovascular Surgchest. Over the past years, we and others have been working
on a nonsurgical approach. We18 have already reported the
use of a preshaped self-expandable stent forming a double
cylinder. The external cylinder allowed anchoring to the di-
lated RVOT. The internal diameter was calibrated to autho-
rize the fixation of commercially available valved stents.
Several modifications of the original design were made to
fit with the anatomy of patients in need of valve replacement.
We19 recently reported the use of such a stent in animals. Al-
though the design was promising, the delivery of the device
remained complicated and needed multiple maneuvers at the
time of deployment. These complications forced us to re-
think the shape of the stent. Moreover, the stability of the
stent had been tested in animals with a native RVOT. To
test the stability in a larger RVOT, we conducted and report
here an experimental study with optimized design of the PA
filler in an ovinemodel with large and asymmetrical RVOTs.
METHODS
PA Filler
The filler is a self-expandable stent constructed from a single 0.22-mm
nitinol wire (AMF, Reuilly, France) in the shape of a cylinder with a double
diameter. The extremities are directed inward and back toward an interme-
diate position forming a second wall in parallel with the external one. In
comparison, in the previous design, the extremities were directed outward
and back toward the middle part. This simple modification facilitates the de-
livery of the device, avoiding extra handling for its deployment (Figure 1).
Besides the improvement of the delivery, the new configuration offers
a larger surface of contact with the wall of the PA. To guarantee the sealing,
we sutured a 0.3-mm polytetrafluoroethylene (PTFE) membrane along the
device with a 4-0 Prolene polypropylene thread (Ethicon, Inc, Somerville,ery c January 2010
Basquin et al Evolving Technology/Basic ScienceFIG
The
preAbbreviations and AcronymsUR
ex
viouPA ¼E 1. C and
tremities are
s design, thpulmonary arteryPTFE ¼ polytetrafluoroethylene
PV ¼ pulmonary valve
PVI ¼ pulmonary valve incompetence
RV ¼ right ventricle (ventricular)
RVOT ¼ right ventricular outflow tractNJ). The device was available with various external diameters from 30 to 40
mm by increments of 5 mm. The size of the device was chosen according to
the grouping (see below). The overall lengths of the deployed and crimped
device were, respectively, 20 and 35mm. The delivery system is a 20FMul-
lins sheath (Medtronic, Inc, Minneapolis, Minn). No balloons were required
for its delivery.
Preparation of the Valved Stent
The valved stents are prepared as previously reported using bicuspid or
tricuspid 22-mm valves harvested in a slaughterhouse from the bovine jug-
ular vein. These valves are sutured in our laboratory with a 4-0 Ti-Cron
thread (Covidien,Norwalk, Conn) into a balloon-expandable stent (CP stent;
NuMED, Inc, Hopkinton, NY). Two lengths of CP stent are used: CP8Z34
and CP8Z28. Once prepared, valved stents are stored in a solution of glutar-
aldehyde. The delivery systemusedwas very similar to the one developed by
NuMED, Inc, for the insertion of the Melody valve (Ensemble). It was con-
stituted by a 22-mm balloon in a balloon catheter with a long sheath sliding
over it. The distal part where the valved stent is crimped over the balloonwas
20F. Beyond this initial 5-cm section, the catheter was 14F.D, The newly designed stent is shown uncovered (front and l
directed inward and back toward an intermediate position fo
e extremities were directed outward and back toward the mid
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Thirty-three sheep weighing 60 to 75 kg were included in the study. We
first intended to enlarge the RVOT and create PVI in all. After recovery, we
planned for the animals to receive the PA filler immediately followed by the
insertion of a valved stent through a transcatheter approach. All animals
were treated according to European regulations for animal experimentation.
The study was reviewed and approved by a local ethical committee. Survi-
vors of the initial operation (n¼ 30) were divided into 3 groups according to
the time when they were humanely killed. Operations in groups 1, 2, and 3
were performed sequentially starting with group 1. Six animals were in-
cluded in a feasibility group and humanely killed just after filler and valve
insertions (group 1). The remaining 24 animals were equally divided into 2
groups and humanely killed after a follow-up of 1 (group 2) or 2 months
(group 3). In each of the 2 latter groups, animals were prospectively divided
into 2 subgroups depending on the diameter of the implant to be inserted.
Animals included in subgroup A received a filler 0 to 4 mm larger than
the diameter of the PA, whereas animals included in subgroup B received
a filler at least 5 mm larger than the measured PA diameter.
Creation of the Model
Anesthesia was induced with 10 mg/kg of thiopental and maintained
with halothane (1%–5%) under mechanical ventilation. A left thoracotomy
was performed in the fourth intercostal space to expose the RVOT. The cir-
cumference of the PA was measured by sliding a noose around the PA. A
pericardial patch was then prepared with the idea of constructing an
RVOT of 40 mm in diameter (circumference 120 mm) by 35 mm in length.
A vascular clamp was positioned laterally on the main PAwith the PV being
roughly in one third of the incision. After 1 or 2 minutes of partial clamping
to verify hemodynamic stability, an incision of 40 mm in length was per-
formed. A leaflet of the PVwas then excised. The prepared pericardial patch
was thereafter stitched on the edges of the incision with a 5-0 Prolene poly-
propylene thread (Figure 2). Hemostasis was controlled by partial openingateral views) and compared with the old design on the top panels (A and B).
rming a second wall in parallel with the external one. In comparison, in the
dle part.
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FIGURE 2. Surgical views showing the various steps of the enlargement of the RVOT. A, Incision through a left thoracotomy showing the RVOT with the
PA at the top. B, Excision of a pulmonary valve leaflet after partial crossclamping of the PA. C, Sewing of the pericardial patch. D, Final aspect of the RVOT.
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sealing. When satisfactory, the clamp was completely removed and the tho-
rax was closed over a thoracic drain. The latter was removed 1 hour after the
operation. Tramadol and antibiotics were administrated to animals for 24
hours. The animals were then allowed to recover for at least 8 weeks.
Insertion of the PA Filler
Cardiac catheterization was performed under general anesthesia in me-
chanically ventilated sheep. Anesthesia was induced by an intravenous in-
jection of thiopental, 10 mg/kg, and was maintained with inhaled
halothane. Cardiac and respiratory functions were monitored throughout
the procedure. A sheath was placed in the right jugular vein. A 5F right cor-
onary catheter (Cordis SA, France) was advanced in the distal PA. A stiff
0.035-inch extrastiff guidewire was then placed through the catheter in
the distal PA. A 5F catheter with radiopaque markers was used for hemody-
namic assessment and dye injection. The PA was measured at the level of
the aneurysm in both systole and diastole. For device selection, the maxi-
mum diameter was considered. Inflation of a compliant balloon (PTS;
NuMED, Inc) was also used to appreciate the distensibility. After measure-
ment and according to the subgrouping, a filler was selected and crimped in
the delivery system. This latter was advanced over the wire in the enlarged
RVOT. The delivery was achieved only by the simple tasks of removing the
sheath and uncovering the device. No other maneuver was necessary to con-
figure the device, which was placed at the level of the enlargement and prox-
imal to the native valve (Figure 3). The delivery system was then removed,
with the wire left in position.
Insertion of the Valved Stent
Immediately after the insertion of the filler, the valved stentwas loaded into
its delivery systemand advanced over the samewire up to the PA.When in the
central part of the filler, the valved stentwas uncovered and balloonswere sub-
sequently inflated to deploy the valve. If necessary, its position was adjusted
before the inflation of the second balloon. After deflation, the delivery system
was removed. The wire was left in place until the final evaluation.Evaluation
In the short-term group (group 1), we only assessed the feasibility of
the filler insertion. No hemodynamic study was performed. In animals200 The Journal of Thoracic and Cardiovascular Surgfrom groups 2 and 3, a complete hemodynamic study was performed
using a marked catheter before the implantation procedure. Pressures
in all right cavities were measured. Two different angiograms in the lat-
eral view were done: one in the RV to assess its size and one in the PA
to assess the anatomy and diameter of the PA and to look for PVI. To
avoid unwanted mobilization of the filler, we made no measurements af-
ter its insertion. After valve insertion, the same measurements were re-
peated to quantify the gradient across the prosthesis, the sealing of the
filler, and the presence of PVI. Cardiac catheterization was repeated
each month until the animals were humanely killed. Paraprosthetic or
prosthetic leakage was sought on the 2 different angiograms. ‘‘Proximal
leakage’’ was defined as leakage observed during the RV angiogram
whereas distal leakage was defined as leakage seen during the PA
angiogram.
Graft Retrieval
The animals were humanely killed after complete assessment at the end
point determined by the protocol. A left thoracotomywas performed and the
lungs and heart were retrieved en bloc after a lethal injection of thiopental.
The pulmonary vascular tree was inspected macroscopically, focusing on
the pulmonary wall, device position, aspect of the pericardial patch, and
the native PA valve. RVOTs were preserved in a formaldehyde solution.
Specimens were embedded in methylmethacrylate. Various stains were per-
formed (von Kossa, orcein, hematoxylin and eosin, and Masson’s tri-
chrome) to study in particular the interface between the arterial wall and
the device. Histologic examination was performed only in animals from
group 3.
Statistical Analysis
Data are presented as mean and range. The Student paired t test was used
to evaluate the difference between subgroups A and B.RESULTS
Animal Model
Thirty-three animals were operated on. Three animals
died either at the time of surgery (n ¼ 2) or before the sec-
ond stage (n ¼ 1). One died of a hemorrhage when theery c January 2010
FIGURE 3. Angiographic views showing the delivery of the PA filler. In each panel (A–D) an in vitro photograph is provided, showing the opening of the
device in a plastic tube.
FIGURE 4. Angiograms before insertion of the filler showing the variable anatomy of the RVOT obtained with patch enlargement.
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TABLE 1. Characteristics of animals from group 1
Group 1
MPA circumference
after surgery (mm)
MPA diameter
after surgery (mm)
MPA diameter at
follow-up (mm)
Time between surgery
and insertion of filler (d)
RV
dilation*
RV
failure* PVI
Filler
(mm)
1 110 35 34 0 — — — 40y
2 120 38.2 35 94 1 0 Severe 40y
3 115 36.6 31 86 0 0 Moderate 35
4 110 35 30 115 1 1 Severe 35
5 108 34.4 33 100 0 0 Severe 35
6 120 38.2 36 70 1 0 Severe 40
Mean 113.8 36.2 33.2 77.5 3/5 1/5 NA NA
MPA, Main pulmonary artery; RV, right ventricular; PVI, pulmonary valve incompetence; NA, not applicable. *1, present; 0, absent. yTransventricular insertion of the filler.
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Scrossclamp was being released, and another had a refractory
ventricular arrhythmia during crossclamping of the RVOT.
The last one died at the time of the second stage during an-
esthetic induction. Autopsy showed a severely enlarged
RV with pleural effusion. In the remaining 30 animals,
no complication occurred from the initial operation to the
second stage. One animal from group 1 had a cardiac arrest
at induction but was successfully resuscitated. The mean
baseline diameter of the PA was 25.3 mm, ranging fromFIGURE 5. Angiograms showing the insertion of the valved stent inside the P
catheter. C, Inflation of the outer balloon catheter. D, Aspect after full deploym
202 The Journal of Thoracic and Cardiovascular Surg19.1 to 29.2 mm. This mean diameter was augmented
with patch enlargement to 36.2 mm (range, 31.8–40
mm). Valvular excision was possible in 31 of 33 animals.
In 2 cases, the leaflet was not caught in the vascular clamp.
In those, we tried to suture the leaflet from the outside after
patch suture and release of the clamp. We were successful
in only 1 of the 2. As a result, 96% of the animal had pul-
monary regurgitation. The recovery period lasted a mean of
89 days (range, 60–191 days). The anatomy of the enlargedA filler. A, Placement of the valved stent. B, Inflation of the inner balloon
ent of devices.
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Basquin et al Evolving Technology/Basic ScienceRVOT was variable despite similar surgical technique.
Examples are given in Figure 4. The angiographic diameter
of the PA was smaller, varying from 30 to 40 mm (mean,
33.3 mm).S
y
st
o
li
c
g
ra
d
ie
n
t
ro
ss
d
ev
ic
es
t
in
se
rt
io
n
(m
m
H
g
)
S
y
st
ol
ic
g
ra
d
ie
n
t
a
cr
o
ss
d
ev
ic
es
a
t
fo
ll
o
w
-u
p
(m
m
H
g)
T
im
e
b
et
w
ee
n
v
a
lv
e
im
p
la
n
t
a
n
d
a
u
to
p
sy
(d
)
9
8
3
2
4
1
0
4
2
1
1
4
3
0
0
0
2
8
7
0
3
2
6
5
2
8
8
1
0
3
2
0
0
3
2
6
7
3
5
7
6
3
2
5
5
3
4
7
5
3
5
7
6
3
2
.7
co
n
d
v
al
v
ed
st
en
t
to
ex
cl
u
d
e
th
e
re
co
rd
ed
le
ak
.Animals from Group 1: Feasibility Group
The filler could be deployed and successfully placed in the
enlarged part of the PA in all animals (Table 1). Implantation
was made transventricularly in the first 2 animals and percu-
taneously in the other. The transventricular approach was
chosen electively in 1 animal and after unsuccessful ad-
vancement of the delivery system in another. Both insertions
were successful. After the animals were humanely killed,
macroscopic study confirmed the angiographic statements
showing the correct deployment, location, and impaction
of the devices on the vascular wall.T
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Animals (n¼ 12) successfully received the filler and sub-
sequently the PV via the transvenous approach (Figure 5 and
Table 2). Angiograms confirmed the good deployment and
placement of the devices away from the PA bifurcation.
No regurgitation or leak was noticed in 9 of 12 animals. In
those, dye injection in the RV did allow visualization of
the aneurysmal RVOT. The filler–valve assembly was per-
fectly molded in all (Figure 6). Respectively, 2 and 1 animals
from groups 2A and 2B had a significant paraprosthetic leak
(Figure 7). In the animal from group 2B, the valved stent was
placed too far proximally, allowing a persisting gap between
the inner part of the filler and the extremity of the valved
stent. Oversizing of the filler fully explained the gap, making
insertion of an 8Z28 stent too short to cover it. This leak was
treated by the insertion of a longer valved stent (8Z34). In the
remaining 2 animals, the paraprosthetic leak was important,
almost completely filling the aneurysmal RVOT. Excluding
animals with leak, the systolic gradient across the devices
was as low as a mean of 7 mm Hg (range, 4–11 mm Hg).
All animals survived to follow-up. All devices were in
good position. No embolization occurred. At 1 month
(mean, 32.7; range, 28–42 days), the mean transprosthetic
gradient was stable at 6 mm Hg (range, 0–10 mm Hg).
The paraprosthetic leak from the 2 animals (group 2A)
was unchanged and none appeared in the other animals. At
autopsy, all devices were almost completely fixed to the
PA, making their retrieval impossible. One PTFE membrane
was broken, which explained the leak seen in this animal. In
the second animal with a leak, the filler was not against the
anterior wall of the PA. At this level, the filler was not fixed
to the PA. A fresh thrombus was present, fully indicating the
location of the leak suspected on angiograms. Entry and exit
points were at the same level. As in others, retrieval of the
filler from the PA was not possible. All valvular implants
were thin and mobile.The Journal of Thoracic and Cardiovascular Surgery c Volume 139, Number 1 203
FIGURE 6. Angiograms after dye injection showing the function of implanted devices (equivalent of a lateral view). A, Right ventriculogram showing the
perfect sealing of the device and the reduction of PA diameter. B, PA injection showing good function of the implanted valve.
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The transvenous insertion of the PA filler was possible in
all (12 of 12). In 1 animal, because no larger device was
available, a 40-mm filler was implanted in a 40-mm PA
(animal initially allocated to group 3B but reallocated to
group 3A). During retrieval of the delivery system, the de-
vice migrated next to the PA bifurcation. We decided not to
proceed with valve insertion and the animal was humanely
killed. Except in this animal, all fillers were perfectly stable
and a valved stent was subsequently inserted. In one in-
stance, a defective stent burst the balloon at the end of
the inflation, making its deflation impossible. The animal
died before we could retrieve the delivery catheter (group
3B). In the remaining 10 animals, the procedure was un-
eventful (Table 3). Angiograms showed good deployment
and position of the devices, but a paraprosthetic leak was
present in 3 of 10. In 1 animal, the leak was moderate
and present only on the PA injection and not on the RV in-FIGURE 7. Left, Angiograms showing the RVOT after insertion of the devices
represented by the presence of contrast dye around the filler. Right, The aspect
embedded in the anterior part of the RVOT, which completely explains the leak
204 The Journal of Thoracic and Cardiovascular Surgjection (‘‘distal leak’’); the dye washout was very slow. All
animals were from group 3A. Excluding these animals, the
mean transprosthetic gradient was 6 mm Hg (range, 1–10
mm Hg).
All animals (excluding the animal undergoing unsuccess-
ful implantation) survived to follow-up. At 1 and 2 months
of follow-up, no embolization occurred. One animal died
at anesthetic induction and could not be tested at 2 months’
follow-up. At autopsy, the valved stent was severely ob-
structed by valvular calcifications. In tested animals, the
transprosthetic gradient remained in the same range at the
two evaluations: 7 mm Hg (range, 4–8 mm Hg) and 5 mm
Hg (range, 0–8), respectively. A paraprosthetic leak was
present in the same 3 animals. It was trivial to moderate in
the animal with the distal leak (ie, leak seen only on the pul-
monary angiogram). Autopsy was performed after a mean
follow-up of 8.9 weeks (range, 7–16 weeks). Because of
a scheduling problem, 1 animal was humanely killed at 16in an animal with an undersized filler. Note the significant paravalvular leak
of the RVOT at autopsy after opening of the anterior wall. The filler is not
seen on angiograms.
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Sweeks. Endothelialization of devices was complete. Devices
were completely embedded in the vascular wall and impos-
sible to retrieve. Fillers and valved stents formed one unique
block. Twice, a fixation defect was present anteriorly or pos-
teriorly, fully explaining the leak seen on RV and PA angio-
grams. The last leak was due to a small hole in the PTFE
membrane on the distal part of the filler (‘‘distal leak’’).
No fixation defect was found in this animal. Valve implants
(except the one described previously) were thin and mobile
in all animals.
Histologic Study
Histologic findings were similar in all animals (Figures 8
and 9). A fibroblastic proliferation was noticed between the
nitinol stent and vascular wall. Few inflammatory cells were
present close to the PTFE membrane and especially in con-
nection with the threads. No necrotic area was noticed. In ad-
dition, a fibroblastic proliferation was found within the
middle part of the nitinol stent. Loose connective tissue
was finally observed between the nitinol and valved stents
except in the area in contact with PTFE membrane, where
a thin and dense layer of fibroblasts was present. Valve im-
plants appeared normal in every case except in the animal
with macroscopic calcifications. Elsewhere, no inflamma-
tory infiltrate or calcifications were present (Figure 9, D).
DISCUSSION
Transcatheter PV insertion technique is still inaccessible
to the wide majority of patients who have a native RVOT ex-
ceeding 22 mm in diameter. We intended to test a device that
intravascularly reduces the diameter of the PA and permits
subsequent insertion of a commercially available valved
stent. Although feasibility and anchorage were demonstrated
in a previous study, the design had to be improved to facil-
itate the deployment.18,19 Moreover, the anchorage proper-
ties of the filler had to be tested in wide and asymmetrical
RVOTs. We imagined an animal model with enlarged
RVOTs. Thirty-three animals were operated on and had
PA enlargement with a pericardial patch and the creation
of a pulmonary leak. Three animals died after this operation.
Significant PVI was achieved in the great majority, leading
to dilation of the RV. As expected, the PA was enlarged
with a mean diameter of 36.2 mm.
Insertion of the Filler and Subsequent Complications
All fillers were inserted successfully. The modifications
made to the configuration of the device improved its de-
ployment and placement as compared with a previous
study.19 No extra handling was needed to release the filler.
We encountered only one embolization over 30 implants.
This occurred suddenly in an animal in which we im-
planted a device with a diameter equal to the diameter of
the enlarged PA. Besides this embolization, we faced a par-
aprosthetic leak in 25% of the animals. The leak wasrdiovascular Surgery c Volume 139, Number 1 205
FIGURE 8. Histologic views (trichrome). A and B, Loose connective tissue between the nitinol (black circle on the right) and valved stents (trichrome350).
C, Magnification of panel A (trichrome3100). D, Overview of the vascular wall (star) with the nitinol stent (arrowhead), valved stent (arrow), and bovine
arterial wall (triangle).
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Srelated to undersizing of the device. Indeed, 5 (83%) of the
6 leaks occurred in animals in which the size of the device
was less than 5 mm greater than the PA diameter (P< .05).
This confirms that oversizing the device is mandatory forFIGURE 9. Histologic views (Stevenel Blue). A, Dense connective tissue betwe
infiltrate between the nitinol stent and the arterial wall (3200). D, Valve implan
206 The Journal of Thoracic and Cardiovascular Surgstent anchoring and ultimately for definitive fixation to
the vascular wall. Although mandatory, oversizing should
not be excessive. In 1 animal, the device was oversized
by 10 mm, resulting in a stable but less than fully deployeden the nitinol stent and the arterial wall (3100). B and C,Mild inflammatory
t with normal thickness (350).
ery c January 2010
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Sdevice. As a consequence, the space between the extremi-
ties in the valve receiving part of the filler was enlarged.
This complication was not anticipated, and the inserted
valved stent was too short to cover the entire gap, leading
to the insinuation of blood between the two devices. This
leak was further excluded by insertion of a longer valved
stent. PTFE membrane breaks were also a source of para-
prosthetic leak in 2 animals (of 6 paraprosthetic leaks).
PV Insertion
PV replacement was possible in 28 of 29 animals without
any complication. In 1 animal, the balloon ruptured during
its inflation because of a defective valved stent. Its deflation
was impossible and the animal died before the delivery sys-
tem could be retrieved. Excluding this animal, insertion was
uneventful and easily done without the need for contrast dye
injection. As previously shown, hemodynamic studies per-
formed immediately and during follow-up did not show
a significant RV–PA gradient in the majority of animals.
One animal with a calcified valve and probable elevated
RV pressure could not be assessed because it died at induc-
tion before evaluation.
Limitations to the Study and Unanswered Questions
Even if the model offers a new feature to test devices for
large RVOTs, the obtained anatomy is still very different
from that seen in postoperative Fallot patients in need of
PV replacement. However, we were able to create a good
model of an enlarged and asymmetrical RVOT and PVI.
The plasticity of the device was very good, making it ade-
quate to conform to all created RVOT anatomy. Whether
this would apply to human anatomy with calcified or noncal-
cified RVOT and with noncircumferential cross-sectional
shape remains to be proven.
The described animal model led to PVI. As a result, ani-
mals had significant RV dilatation (77%) and/or dysfunc-
tion (30%). Unfortunately, these features were assessed
subjectively with angiograms and hemodynamic data. A
more quantitative way, such as magnetic resonance imaging,
to assess this dysfunction would be very useful, but this im-
aging modality is not presently available in our animal lab-
oratory.
Although we were able to show that oversizing is prefer-
able in animals, this could be very different in humans and
will need proper studies. In our study, the simple measure-
ments of the maximum diameter of the PA were sufficient
to choose the proper device. In the clinical setting, a more
sophisticated approach such as the use of compliant balloon
catheters might be useful to improve device selection. In ad-
dition, having a device in the RVOT might, at least theoret-
ically, increase the risk of thrombus formation. Even if we
did not observe such a complication in animals, a protocol
of prophylaxis with antithrombotic agents will need to be
refined in humans. Finally, despite considerable improve-The Journal of Thoracic and Caments in stent design, a more direct procedure would be pref-
erable. We are, indeed, in the process of developing an
integrated valved stent that could be inserted in one step in
the enlarged PA.CONCLUSIONS
The realization of an ovine model of a large and asymmet-
rical RVOT was possible with a small learning curve. We
were able to reproduce the RVOT enlargement with a patch
and the presence of a pulmonary regurgitation with repercus-
sions on the RV. The deployment of the new design of the
filler was possible in the vast majority of animals. The choice
of device size is critical to avoid complications such as em-
bolization and paraprosthetic leak.
We thank Philippe Marx, who developed this new stent in
cooperation with Younes Boudjemline. We also thank Professor
D. Hannouche and Mr Myrtil for their technical support in the
histologic studies.References
1. Nollert G, Fischlein T, Bouterwek S, Bo¨hmer C, Klinner W, Reichart B. Long-
term survival in patients with repair of tetralogy of Fallot: 36-year follow-up of
490 survivors of the first year after surgical repair. J Am Coll Cardiol. 1997;30:
1374-83.
2. Murphy JG, Gersh BJ, Mair DD, Fuster V, McGoonMD, Ilstrup DM, et al. Long-
term outcome in patients undergoing surgical repair of tetralogy of Fallot. N Engl
J Med. 1993;329:593-9.
3. Hamada H, Terai M, Jibiki T, Nakamura T, Gatzoulis MA, Niwa K. Influence of
early repair of tetralogy of Fallot without an outflow patch on late arrhythmias and
sudden death: a 27-year follow-up study following a uniform surgical approach.
Cardiol Young. 2002;12:345-51.
4. Silka MJ, Hardy BG, Menashe´ VD, Morris CD. A population-based prospective
evaluation of risk of sudden cardiac death after operation for common congenital
heart defects. J Am Coll Cardiol. 1998;32:245-51.
5. Gatzoulis MA, Till JA, Somerville J, Redington AN. Mechanoelectrical interac-
tion in tetralogy of Fallot. QRS prolongation relates to right ventricular size and
predicts malignant ventricular arrhythmias and sudden death. Circulation. 1995;
92:231-7.
6. Deanfield JE, McKenna WJ, Presbitero P, England D, Graham GR, Hallidie-
Smith K. Ventricular arrhythmia in unrepaired and repaired tetralogy of Fallot.
Relation to age, timing of repair, and haemodynamic status. Br Heart J. 1984;
52:77-81.
7. Dietl CA, Cazzaniga ME, Dubner SJ, Pe´rez-Balin˜o NA, Torres AR, Favaloro RG.
Life-threatening arrhythmias and RV dysfunction after surgical repair of tetralogy
of Fallot. Comparison between transventricular and transatrial approaches. Circu-
lation. 1994;90(5 Pt 2):II7-12.
8. Hokanson JS, Moller JH. Significance of early transient complete heart block as
a predictor of sudden death late after operative correction of tetralogy of Fallot.
Am J Cardiol. 2001;87:1271-7.
9. Bove EL, Kavey RE, Byrum CJ, Sondheimer HM, Blackman MS, Thomas FD.
Improved right ventricular function following late pulmonary valve replacement
for residual pulmonary insufficiency or stenosis. J Thorac Cardiovasc Surg.
1985;90:50-5.
10. Bove EL, Byrum CJ, Thomas FD, Kavey RE, Sondheimer HM, Blackman MS,
et al. The influence of pulmonary insufficiency on ventricular function following
repair of tetralogy of Fallot: evaluation using radionuclide ventriculography. J
Thorac Cardiovasc Surg. 1983;85:691-6.
11. Harrison DA, Harris L, Siu SC, MacLoghlin CJ, Connelly MS, Webb GD, et al.
Sustained ventricular tachycardia in adult patients late after repair of tetralogy of
Fallot. J Am Coll Cardiol. 1997;30:1368-73.
12. de Ruijter FT, Weenink I, Hitchcock FJ, Meijboom EJ, Bennink GB. Right ven-
tricular dysfunction and pulmonary valve replacement after correction of tetralogy
of Fallot. Ann Thorac Surg. 2002;73:1794-800.rdiovascular Surgery c Volume 139, Number 1 207
Evolving Technology/Basic Science Basquin et al
E
T
/B
S13. Bonhoeffer P, Boudjemline Y, Saliba Z, Hausse AO, Aggoun Y, Bonnet D, et al.
Transcatheter implantation of a bovine valve in pulmonary position: a lamb study.
Circulation. 2000;102:813-6.
14. Bonhoeffer P, Boudjemline Y, Qureshi SA, Le Bidois J, Iserin L, Acar P, et al. Per-
cutaneous insertion of the pulmonary valve. J Am Coll Cardiol. 2002;39:1664-9.
15. Lurz P, Coats L, Khambadkone S, Nordmeyer J, Boudjemline Y, Schievano S,
et al. Percutaneous pulmonary valve implantation: impact of evolving technology
and learning curve on clinical outcome. Circulation. 2008;117:1964-72.
16. Berdat PA, Carrel T.Off-pumppulmonary valve replacementwith the newShelhigh
Injectable Stented Pulmonic Valve. J Thorac Cardiovasc Surg. 2006;131:1192-3.208 The Journal of Thoracic and Cardiovascular Surg17. Schreiber C, Vogt M, Bauernschmitt R, Prodan Z, Tassani P, Eicken A, et al. Pul-
monary valve implantation with a self-expanding stented valve: 1-year follow-up
in the first patient. Ann Thorac Surg. 2006;82:2340.
18. Boudjemline Y, Agnoletti G, Bonnet D, Sidi D, Bonhoeffer P. Percutaneous pul-
monary valve replacement in a large right ventricular outflow tract: an experimen-
tal study. J Am Coll Cardiol. 2004;43:1082-7.
19. Mollet A, Basquin A, Stos B, Boudjemline Y. Off-pump replacement of the
pulmonary valve in large right ventricular outflow tracts: a transcatheter ap-
proach using an intravascular infundibulum reducer. Pediatr Res. 2007;62:
428-33.ery c January 2010
